These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 30309389)

  • 1. Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study.
    Scheltens P; Hallikainen M; Grimmer T; Duning T; Gouw AA; Teunissen CE; Wink AM; Maruff P; Harrison J; van Baal CM; Bruins S; Lues I; Prins ND
    Alzheimers Res Ther; 2018 Oct; 10(1):107. PubMed ID: 30309389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glutaminyl Cyclase Inhibitor PQ912 Improves Cognition in Mouse Models of Alzheimer's Disease-Studies on Relation to Effective Target Occupancy.
    Hoffmann T; Meyer A; Heiser U; Kurat S; Böhme L; Kleinschmidt M; Bühring KU; Hutter-Paier B; Farcher M; Demuth HU; Lues I; Schilling S
    J Pharmacol Exp Ther; 2017 Jul; 362(1):119-130. PubMed ID: 28446518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In pursuit of a sensitive EEG functional connectivity outcome measure for clinical trials in Alzheimer's disease.
    Briels CT; Stam CJ; Scheltens P; Bruins S; Lues I; Gouw AA
    Clin Neurophysiol; 2020 Jan; 131(1):88-95. PubMed ID: 31759193
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD.
    Vijverberg EGB; Axelsen TM; Bihlet AR; Henriksen K; Weber F; Fuchs K; Harrison JE; Kühn-Wache K; Alexandersen P; Prins ND; Scheltens P
    Alzheimers Res Ther; 2021 Aug; 13(1):142. PubMed ID: 34425883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects.
    Lues I; Weber F; Meyer A; Bühring U; Hoffmann T; Kühn-Wache K; Manhart S; Heiser U; Pokorny R; Chiesa J; Glund K
    Alzheimers Dement (N Y); 2015 Nov; 1(3):182-195. PubMed ID: 29854937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer's disease (BLAZE).
    Salloway S; Honigberg LA; Cho W; Ward M; Friesenhahn M; Brunstein F; Quartino A; Clayton D; Mortensen D; Bittner T; Ho C; Rabe C; Schauer SP; Wildsmith KR; Fuji RN; Suliman S; Reiman EM; Chen K; Paul R
    Alzheimers Res Ther; 2018 Sep; 10(1):96. PubMed ID: 30231896
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABT-126 monotherapy in mild-to-moderate Alzheimer's dementia: randomized double-blind, placebo and active controlled adaptive trial and open-label extension.
    Gault LM; Lenz RA; Ritchie CW; Meier A; Othman AA; Tang Q; Berry S; Pritchett Y; Robieson WZ
    Alzheimers Res Ther; 2016 Oct; 8(1):44. PubMed ID: 27756421
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter, randomized, double-blind, placebo-controlled ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamic (PD) effects of Posiphen in subjects with early Alzheimer's Disease.
    Galasko D; Farlow MR; Lucey BP; Honig LS; Elbert D; Bateman R; Momper J; Thomas RG; Rissman RA; Pa J; Aslanyan V; Balasubramanian A; West T; Maccecchini M; Feldman HH
    Alzheimers Res Ther; 2024 Jul; 16(1):151. PubMed ID: 38970127
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring the binding mode of PQ912 against secretory glutaminyl cyclase through systematic exploitation of conformational ensembles.
    Chandran R; Dileep KV
    Chem Biol Drug Des; 2021 Nov; 98(5):850-856. PubMed ID: 34423556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of the γ-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease.
    Coric V; van Dyck CH; Salloway S; Andreasen N; Brody M; Richter RW; Soininen H; Thein S; Shiovitz T; Pilcher G; Colby S; Rollin L; Dockens R; Pachai C; Portelius E; Andreasson U; Blennow K; Soares H; Albright C; Feldman HH; Berman RM
    Arch Neurol; 2012 Nov; 69(11):1430-40. PubMed ID: 22892585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protocol for a seamless phase 2A-phase 2B randomized double-blind placebo-controlled trial to evaluate the safety and efficacy of benfotiamine in patients with early Alzheimer's disease (BenfoTeam).
    Feldman HH; Luchsinger JA; Léger GC; Taylor C; Jacobs DM; Salmon DP; Edland SD; Messer K; Revta C; Flowers SA; Jones KS; Koulman A; Yarasheski KE; Verghese PB; Venkatesh V; Zetterberg H; Durant J; Lupo JL; Gibson GE;
    PLoS One; 2024; 19(5):e0302998. PubMed ID: 38809849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease.
    Prins ND; Harrison JE; Chu HM; Blackburn K; Alam JJ; Scheltens P;
    Alzheimers Res Ther; 2021 May; 13(1):106. PubMed ID: 34044875
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.
    Decourt B; Drumm-Gurnee D; Wilson J; Jacobson S; Belden C; Sirrel S; Ahmadi M; Shill H; Powell J; Walker A; Gonzales A; Macias M; Sabbagh MN
    Curr Alzheimer Res; 2017; 14(4):403-411. PubMed ID: 28124585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease.
    Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP
    Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study to evaluate the effect of CT1812 treatment on synaptic density and other biomarkers in Alzheimer's disease.
    van Dyck CH; Mecca AP; O'Dell RS; Bartlett HH; Diepenbrock NG; Huang Y; Hamby ME; Grundman M; Catalano SM; Caggiano AO; Carson RE
    Alzheimers Res Ther; 2024 Jan; 16(1):20. PubMed ID: 38273408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.
    Burns DK; Alexander RC; Welsh-Bohmer KA; Culp M; Chiang C; O'Neil J; Evans RM; Harrigan P; Plassman BL; Burke JR; Wu J; Lutz MW; Haneline S; Schwarz AJ; Schneider LS; Yaffe K; Saunders AM; Ratti E;
    Lancet Neurol; 2021 Jul; 20(7):537-547. PubMed ID: 34146512
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, tolerability, and antibody response of active Aβ immunotherapy with CAD106 in patients with Alzheimer's disease: randomised, double-blind, placebo-controlled, first-in-human study.
    Winblad B; Andreasen N; Minthon L; Floesser A; Imbert G; Dumortier T; Maguire RP; Blennow K; Lundmark J; Staufenbiel M; Orgogozo JM; Graf A
    Lancet Neurol; 2012 Jul; 11(7):597-604. PubMed ID: 22677258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varoglutamstat: Inhibiting Glutaminyl Cyclase as a Novel Target of Therapy in Early Alzheimer's Disease.
    Feldman HH; Messer K; Qiu Y; Sabbagh M; Galasko D; Turner RS; Lopez O; Smith A; Durant J; Lupo JL; Revta C; Balasubramanian A; Kuehn-Wache K; Wassmann T; Schell-Mader S; Jacobs DM; Salmon DP; Léger G; DeMarco ML; Weber F;
    J Alzheimers Dis; 2024; 101(s1):S79-S93. PubMed ID: 39422941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.